News and Announcements
Prescient Therapeutics Ltd FY15 Company Update
- Published February 03, 2015 2:40PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Prescient Therapeutics (ASX:PTX), is a clinical stage oncology company developing small molecule inhibitors of the Ras and AKT signalling pathways to treat a range of cancers of unmet medical need, including breast, multiple myeloma, ovarian and AML. Prescient has added 3 new high profile Non-Executive Director’s Mr Steve Engle, Dr James Campbell and Mr Steven Yatomi-Clarke as well as bolstering it’s Scientific Advisory Board with the addition of Professor Douglas Joshua, a world-leading expert in multiple myeloma.
Prescient has also acquired oncology company, Aktivate Therapeutics finalised on 28 November 2014, a strategic move that deepens the pipeline of exciting products that the company is advancing through the clinic. With a strengthened pipeline and management team, the company has now decided to change name and rebrand as Prescient Therapeutics.
Please click on the ‘Receive Information’ button below for more information or to register your interest.
ABOUT PRESCIENT THERAPEUTICS
Prescient Therapeutics (formerly Virax Holdings) is a clinical stage oncology company developing novel targeted approaches to treat cancers of high unmet need, such as advanced breast, ovarian, multiple myeloma and acute leukemia.
The company raised A$3M in June 2014 and has in the last 6-months acquired a deep pipeline of products through strategic company acquisitions. Prescients’ pipeline includes a small molecule inhibitor PTX-100 (GGTI 2418), capable of blocking the Ras cancer pathway as well as PTX-200 (TCN-P) which inhibits the AKT pathway, another key pathway that contributes to cancer.
Together these novel drugs provide Prescient the unique ability to run five active clinical trials, within the next 12-months, at some of the worlds best Cancer Centers. The aim is to bring to provide better outcomes for cancer patients around the world.
Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
Backed By Leading Investment Groups and Family Offices
